Dennis Chang

Dennis Chang brings a wealth of knowledge and experience in the field of oncology. He has led over 150+ projects, cultivating world-class oncology expertise and remains on the forefront of cancer-related science, medicine, evolving policies, key trends, and biopharma best practices. Dennis leverages this knowledge and experience to help biopharma clients develop strategies for their most challenging and complex problems, such as:

• Target prioritization for new platform technologies
• Indication prioritization for new therapeutic compounds
• Portfolio re-evaluation in light of paradigm-shifting new data
• Identifying the best ‘bets’ to place for preclinical and early clinical assets
• Navigating the evolving economics and science of precision oncology

Dennis embraces his focus on oncology product and portfolio strategies:

“The pace of advancement in cancer science and medicine has never been faster, and the hurdles for commercial success of new oncology therapies have never been higher. Helping biopharma companies adapt and persevere—and thus bring new, better medicines to cancer patients—is incredibly demanding but immensely rewarding.”

Dennis formerly served as managing director at Clarion and has also worked as an academic scientist and educator, holding positions as a Postdoctoral Fellow in the Biology Department at Brandeis University and as a Visiting Assistant Professor in the Biology Department at Wellesley College.

Dennis received a PhD from the Neurobiology Department at Harvard Medical School and a BScH in Life Sciences from Queen’s University in Canada.